Thank you to Andrew Dunn from Endpoints News for the in-depth piece on Isomorphic Labs, exploring the tech we’re developing to reimagine drug discovery using AI, and the passion of the team leading our work to achieve Iso’s mission. In the feature, Andy tracks the timeline of ‘The meteoric rise of Isomorphic Labs (and AI)’ and provides ‘a glimpse behind the curtain into how Hassabis’ AI-driven vision is becoming reality, and why the company believes its pure focus on technology and ideas will lead to success compared with companies taking different approaches.’ Read more here: https://lnkd.in/e7u-GT8G
Isomorphic Labs
Biotechnology Research
We are reimagining the entire drug discovery process from first principles with an AI-first approach.
About us
Isomorphic Labs is a new Alphabet company and commercial venture which aims to reimagine the entire drug discovery process from first principles with an AI-first approach, and, ultimately, to model and understand some of the fundamental mechanisms of life. Using computational advances, we’re working at the cutting edge in the new era of ‘digital biology’. By significantly increasing the pace of scientific research and efficacy of new medicines, we will be at the forefront of breakthroughs that will benefit millions of people.
- Website
-
https://www.isomorphiclabs.com/
External link for Isomorphic Labs
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- London
- Type
- Privately Held
- Founded
- 2021
Locations
-
Primary
Get directions
London, GB
Employees at Isomorphic Labs
Updates
-
Watch the moment our CEO Demis Hassabis receives his Nobel Prize diploma and medal alongside fellow chemistry laureates David Baker and John Jumper at the esteemed Nobel Prize award ceremony: #NobelPrize
”David Baker, Demis Hassabis and John Jumper, your ground-breaking work in computational protein design and protein structure prediction has revolutionised these fields. It has opened up completely new possibilities to design proteins that have never been seen before, and we now have access to predicted structures of all 200 million known proteins. These are truly great achievements.” Watch the very moment the chemistry laureates received their Nobel Prize diplomas and medals during the 2024 Nobel Prize award ceremony. #NobelPrize
-
Tune in to hear Rebecca Paul, Head of Medicinal Drug Design at Isomorphic Labs deliver a flash talk on the Drug Hunter platform, this Thursday 12th December 8am PST, 11am EST or 5pm CEST. Have your questions answered live by Research Leaders Pascal Savy and Adrian Stecuła.
📣Reminder📣 AI-First Drug Design: Accelerating the Discovery of New Therapeutics | https://lnkd.in/gaQqNaT5 Thursday, Dec 12, 2024 8 AM PST / 11 AM EST / 5 PM CEST There is growing interest around the application of artificial intelligence in drug design and discovery. Advanced computational and AI-driven methods have the potential to transform the field by accelerating, augmenting and enhancing drug design, the development process, and clinical trials. Curious to see how those at the forefront of AI see its potential impact in drug discovery? In this Flash Talk, Rebecca Paul, Head of Medicinal Drug Design at Isomorphic Labs, will share her insights on how AlphaFold 3 is applied along with other breakthrough AI models to advance the rational design and optimization of small molecules. This is a presentation you don't want to miss! Register here: https://lnkd.in/g6CfB8Hb
-
-
Isomorphic Labs reposted this
"That got me hooked on computers and AI for the rest of my life." 2024 chemistry laureate Demis Hassabis describes how playing chess competitively at the age of four led him to becoming an AI programmer. From there he went on to solve big problems in biology, developing an AI model to predict the structure of virtually all known proteins. Watch his full Nobel Prize lecture: https://bit.ly/4f77WJi
-
If you are NeurIPS 2024 join Sergei Yakneen and Jörn Jacobsen on Thursday 12th December: 14:00-14:30 to hear more about designing new medicines with AI at Isomorphic Labs. We are hiring! Meet the team and have a chance to ask questions afterwards. You will find us at the Google DeepMind booth. We are evolving the field of drug discovery by developing new AI models like AlphaFold 3 and beyond, allowing us to better understand disease and design new therapeutic molecules in-silico. We can use these models to discover drug candidates. Learn about our cutting-edge AI tech, and some of the most exciting challenges our growing team of AI researchers and engineers are working on currently. More information here: bit.ly/3BrY7Yy #ai #drugdiscovery #NeurIPS2024
-
-
Be sure to catch Max Jaderberg’s TED talk recorded live at #TEDAI San Francisco and hear more about using our AI Analogue of biomolecular systems to rationally design drug molecules and why ‘we are going to need as many people as possible, especially working in machine learning, AI, and tech, to help drive this new wave of progression.’ Watch the full talk here: bit.ly/3Z6YyiU @TEDTalks #AI #DrugDiscovery
At #TEDAI 2024, Max Jaderberg, Chief AI Officer at Isomorphic Labs, discusses how AI is accelerating research, saving an estimated billion years of discovery time. Watch the full talk on ted.com! ➡️ https://lnkd.in/dUedjVaD #AI #DrugDiscovery #HealthcareInnovation #Biotech
-
We are looking forward to seeing you next week at NeurIPS. Come and talk to us about current opportunities at Isomorphic Labs and meet the hiring managers and team working to advance AI-first drug design. Register your interest here: bit.ly/40Vo4tR #ai #drugdiscovery #NeurIPS2024
-
“The technology we already have at our fingertips also opens up new possibilities to tackle diseases that have been previously beyond our reach. Our team of scientists and researchers at IsoLabs has created a whole host of unique AI algorithms. These models work together, allowing us to understand the intricate world of proteins and how they interact with different molecules. This gives us new ways to design molecules, which is incredibly exciting, and we believe it will completely change how we discover and design new drugs.” Read more from our Chief AI Officer Max Jaderberg on how we’re using AlphaFold 3 alongside a suite of AI models to redefine rational drug design in The Atlantic: https://lnkd.in/eWRhEqaZ
The AI-Powered Future of Drug Discovery
theatlantic.com
-
We are looking forward to seeing you at NeurIPS 2024 in Vancouver. Come and talk to us about our open ML Research Engineer roles at Isomorphic Labs. Our hiring managers will be attending. Register your interest here: bit.ly/40Vo4tR #ai #drugdiscovery #NeurIPS2024
-
-
How is AI saving billions of years of human research time? Our Chief AI Officer Max Jaderberg just released a TED talk describing a powerful new paradigm: Our ability to develop AI analogues of the ‘real messy world’ of biology, recreating it with neural network architectures that fuel open-ended scientific discovery to ultimately design new ways to modulate biology. bit.ly/3Z6YyiU Watch to learn more about: ➡️ How AI solved the 50-year protein folding problem with AlphaFold and how we anticipate other breakthroughs of equal magnitude in our life-time ➡️ AI Analogues could reverse the curse of Eroom’s law ➡️ How could we use AI to modulate the function of proteins in cancer to stop this protein’s DNA repairing, leaving just healthy cells remaining ➡️ How AlphaFold 3 diffuses the coordinates of atoms in our biomolecular system giving us a completely malleable virtual biomolecular world ➡️ Instead of having one chemist working on developing new therapeutic designs, we have thousands of agents, guided and nurtured by the human ingenuity of our human chemist instead #AI #DrugDesign #TEDAI
Max Jaderberg: How AI is saving billions of years of human research time
https://www.ted.com